Glucotrack, Inc. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
On July 14, 2026, Glucotrack merged with Lokahi Therapeutics, acquiring its assets for $34.3M in consideration (19.99% common stock + Series A preferred representing 90% total equity post-merger), valued at $12.522/share. Concurrently, Glucotrack raised $7.95M gross in bridge financing ($4.45M on 7/14, $3.5M on 8/4, both convertible notes at 8% coupon, 22% OID, maturing 4-5/2027) plus $2M interim PIPE. The company executed two reverse stock splits: 1-for-15 (8/28/2026) and 1-for-2 (10/26/2026), totaling 1-for-30 combined. Pro forma shows combined H1 2026 net loss of $19.7M on $0 revenue; accumulated deficit reaches $165.4M.
Why this rating
Merger is transformational—assets acquired ($25.4M IPR&D + $15.6M goodwill = $41M) exceed company market cap by 7.6x. Bridge financing + reverse splits signal severe dilution and capital distress. Accumulated losses and zero revenue are critical concerns.
Price action (we called it negative)
before filing · preread $2.05 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.